{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T18:19:13Z","timestamp":1792520353759,"version":"4.5.0"},"reference-count":40,"publisher":"Informa UK Limited","issue":"4","license":[{"start":{"date-parts":[[2020,11,25]],"date-time":"2020-11-25T00:00:00Z","timestamp":1606262400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Leukemia &amp; Lymphoma"],"published-print":{"date-parts":[[2021,3,21]]},"DOI":"10.1080\/10428194.2020.1845332","type":"journal-article","created":{"date-parts":[[2020,11,25]],"date-time":"2020-11-25T08:46:01Z","timestamp":1606293961000},"page":"810-818","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":97,"title":["Safety and efficacy of navitoclax, a BCL-2 and BCL-X\n                    <sub>L<\/sub>\n                    inhibitor, in patients with relapsed or refractory lymphoid malignancies: results from a phase 2a study"],"prefix":"10.1080","volume":"62","author":[{"given":"Sven","family":"de Vos","sequence":"first","affiliation":[{"name":"David Geffen School of Medicine at UCLA, Los Angeles, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John P.","family":"Leonard","sequence":"additional","affiliation":[{"name":"Weill Cornell Medicine and New York-Presbyterian Hospital, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan W.","family":"Friedberg","sequence":"additional","affiliation":[{"name":"Wilmot Cancer Institute, University of Rochester, Rochester, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jasmine","family":"Zain","sequence":"additional","affiliation":[{"name":"City of Hope Comprehensive Cancer Center, Duarte, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kieron","family":"Dunleavy","sequence":"additional","affiliation":[{"name":"George Washington University, Washington, DC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rod","family":"Humerickhouse","sequence":"additional","affiliation":[{"name":"AbbVie, Inc, North Chicago, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Hayslip","sequence":"additional","affiliation":[{"name":"AbbVie, Inc, North Chicago, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Pesko","sequence":"additional","affiliation":[{"name":"AbbVie, Inc, North Chicago, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wyndham H.","family":"Wilson","sequence":"additional","affiliation":[{"name":"George Washington University, Washington, DC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2020,11,25]]},"reference":[{"key":"e_1_3_4_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1097-2765(00)00136-2"},{"key":"e_1_3_4_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0968-0004(00)01740-0"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1059108"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M109939200"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.3874430"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V79.2.495.495"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.1309\/491W-L1TN-UFQX-T61B"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.10139"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V86.5.1903.bloodjournal8651903"},{"key":"e_1_3_4_11_1","first-page":"456","article-title":"Bcl-2 expression in chronic lymphocytic leukemia and its correlation with the induction of apoptosis and clinical outcome","volume":"10","author":"Robertson LE","year":"1996","unstructured":"Robertson LE, Plunkett W, McConnell K, et\u00a0al. Bcl-2 expression in chronic lymphocytic leukemia and its correlation with the induction of apoptosis and clinical outcome. Leukemia. 1996;10:456\u2013459.","journal-title":"Leukemia"},{"issue":"21","key":"e_1_3_4_12_1","first-page":"6101","article-title":"An informatics approach identifying markers of chemosensitivity in human cancer cell lines","volume":"60","author":"Amundson SA","year":"2000","unstructured":"Amundson SA, Myers TG, Scudiero D, et\u00a0al. An informatics approach identifying markers of chemosensitivity in human cancer cell lines. Cancer Res. 2000;60(21):6101\u20136110.","journal-title":"Cancer Res"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1210220"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2006.03.027"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq287"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-07-5836"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(10)70261-8"},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.34.7898"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.4.1244"},{"key":"e_1_3_4_20_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V87.12.4990.bloodjournal87124990"},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.cdd.4402081"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2007.01.037"},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0808036105"},{"issue":"2","key":"e_1_3_4_24_1","article-title":"Phase-II study of navitoclax (ABT-263) safety and efficacy in patients with relapsed or refractory chronic lymphocytic leukemia (CLL): interim results","volume":"96","author":"Seymour F","year":"2011","unstructured":"Seymour F, Roberts A, Carney D, et\u00a0al. Phase-II study of navitoclax (ABT-263) safety and efficacy in patients with relapsed or refractory chronic lymphocytic leukemia (CLL): interim results. Haematologica. 2011;96(suppl 2:227.","journal-title":"Haematologica"},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-009-1232-1"},{"key":"e_1_3_4_26_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-11-0415"},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-5381.2012.02048.x"},{"key":"e_1_3_4_28_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2015.1030638"},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13487"},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3048"},{"key":"e_1_3_4_31_1","unstructured":"U.S. Food and Drug Administration. News & Events. FDA approves new drug for chronic lymphocytic leukemia in patients with a specific chromosomal abnormality. 2016. [cited 2019 Mar 28]. Available from: https:\/\/www.fda.gov\/drugs\/informationondrugs\/approveddrugs\/ucm610308.htm."},{"key":"e_1_3_4_32_1","unstructured":"Genentech. Genentech announces FDA approval for Venclexta plus Rituxan for people with previously treated chronic lymphocytic leukemia. 2018. [cited 2019 Mar 28]. Available from: https:\/\/www.gene.com\/media\/press-releases\/14728\/2018-06-08\/genentech-announces-fda-approval-for-ven."},{"key":"e_1_3_4_33_1","unstructured":"U.S. Food and Drug Administration. Drugs. FDA approves venetoclax for CLL and SLL. 2019. [cited 2019 Nov 11]. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-venetoclax-cll-and-sll."},{"key":"e_1_3_4_34_1","unstructured":"U.S. Food and Drug Administration. Drugs. FDA approves venetoclax in combination for AML in adults. 2018. [cited 2019 Mar 28]. Available from: https:\/\/www.fda.gov\/Drugs\/InformationOnDrugs\/ApprovedDrugs\/ucm626499.htm."},{"key":"e_1_3_4_35_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.70.4320"},{"key":"e_1_3_4_36_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy256"},{"issue":"1","key":"e_1_3_4_37_1","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1182\/blood-2018-99-118519","article-title":"Venetoclax plus rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) improves outcomes in BCL2-positive first-line diffuse large B-cell lymphoma (DLBCL): First safety, efficacy and biomarker analyses from the phase II CAVALLI study","volume":"132","author":"Morschhauser F","year":"2018","unstructured":"Morschhauser F, Feugier P, Flinn IW, et\u00a0al. Venetoclax plus rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) improves outcomes in BCL2-positive first-line diffuse large B-cell lymphoma (DLBCL): First safety, efficacy and biomarker analyses from the phase II CAVALLI study. Blood. 2018;132(Supplement 1):782\u2013782.","journal-title":"Blood"},{"key":"e_1_3_4_38_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-113464"},{"key":"e_1_3_4_39_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0243-z"},{"key":"e_1_3_4_40_1","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2014.525"},{"key":"e_1_3_4_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2011.12.021"}],"container-title":["Leukemia &amp; Lymphoma"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/10428194.2020.1845332","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,22]],"date-time":"2024-11-22T12:24:51Z","timestamp":1732278291000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/10428194.2020.1845332"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,25]]},"references-count":40,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,3,21]]}},"alternative-id":["10.1080\/10428194.2020.1845332"],"URL":"https:\/\/doi.org\/10.1080\/10428194.2020.1845332","relation":{},"ISSN":["1042-8194","1029-2403"],"issn-type":[{"value":"1042-8194","type":"print"},{"value":"1029-2403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,25]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ilal20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ilal20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2020-03-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-10-21","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-10-26","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-11-25","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}